Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer

The LOGIK0902/OLCSG0905 Intergroup Study Protocol

Katsuyuki Hotta, Jiichiro Sasaki, Sho Saeki, Nagio Takigawa, Kuniaki Katsui, Koichi Takayama, Naoyuki Nogami, Yoshiyuki Shioyama, Akihiro Bessho, Junji Kishimoto, Mitsune Tanimoto, Katsuyuki Kiura, Yukito Ichinose

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Herein, we describe an ongoing phase II trial in patients with locally advanced non-small-cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR). Patients with chemotherapy-naive locally advanced disease with active EGFR mutations will receive the induction treatment, specified as gefitinib monotherapy (250 mg/body) for 8 weeks. Patients whose disease has not progressed during the induction therapy will receive cisplatin and docetaxel (40 mg/m2) on days 1, 8, 29, and 36, and concurrent 3-dimensional conformal thoracic radiotherapy with a single daily fraction of 2 Gy, for 5 consecutive days each week to provide a total dose of 60 Gy. The primary end point is overall survival at 24 months. A target sample size of 21 evaluable patients is considered sufficient to validate an expected rate of 85%, and 60% would be the lower limit of interest, with 80% power and a 1-sided α of 5%. Secondary end points include toxicity, response rate, and overall survival. This study will clarify whether tyrosine kinase inhibitors targeted to EGFR can produce a maximal effect in selected NSCLC patients with the relevant driver mutation, even in the locally advanced setting.

Original languageEnglish
JournalClinical Lung Cancer
DOIs
Publication statusAccepted/In press - Aug 8 2015

Fingerprint

Chemoradiotherapy
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
docetaxel
Conformal Radiotherapy
Mutation
Sample Size
Protein-Tyrosine Kinases
Cisplatin
Thorax
Survival Rate
gefitinib
Drug Therapy
Survival
Therapeutics

Keywords

  • Chemoradiation
  • Cure
  • EGFR mutation
  • Locally advanced setting
  • Lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer : The LOGIK0902/OLCSG0905 Intergroup Study Protocol. / Hotta, Katsuyuki; Sasaki, Jiichiro; Saeki, Sho; Takigawa, Nagio; Katsui, Kuniaki; Takayama, Koichi; Nogami, Naoyuki; Shioyama, Yoshiyuki; Bessho, Akihiro; Kishimoto, Junji; Tanimoto, Mitsune; Kiura, Katsuyuki; Ichinose, Yukito.

In: Clinical Lung Cancer, 08.08.2015.

Research output: Contribution to journalArticle

Hotta, Katsuyuki ; Sasaki, Jiichiro ; Saeki, Sho ; Takigawa, Nagio ; Katsui, Kuniaki ; Takayama, Koichi ; Nogami, Naoyuki ; Shioyama, Yoshiyuki ; Bessho, Akihiro ; Kishimoto, Junji ; Tanimoto, Mitsune ; Kiura, Katsuyuki ; Ichinose, Yukito. / Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer : The LOGIK0902/OLCSG0905 Intergroup Study Protocol. In: Clinical Lung Cancer. 2015.
@article{1c394bfe3338476db10584d4e9e55535,
title = "Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol",
abstract = "Herein, we describe an ongoing phase II trial in patients with locally advanced non-small-cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR). Patients with chemotherapy-naive locally advanced disease with active EGFR mutations will receive the induction treatment, specified as gefitinib monotherapy (250 mg/body) for 8 weeks. Patients whose disease has not progressed during the induction therapy will receive cisplatin and docetaxel (40 mg/m2) on days 1, 8, 29, and 36, and concurrent 3-dimensional conformal thoracic radiotherapy with a single daily fraction of 2 Gy, for 5 consecutive days each week to provide a total dose of 60 Gy. The primary end point is overall survival at 24 months. A target sample size of 21 evaluable patients is considered sufficient to validate an expected rate of 85{\%}, and 60{\%} would be the lower limit of interest, with 80{\%} power and a 1-sided α of 5{\%}. Secondary end points include toxicity, response rate, and overall survival. This study will clarify whether tyrosine kinase inhibitors targeted to EGFR can produce a maximal effect in selected NSCLC patients with the relevant driver mutation, even in the locally advanced setting.",
keywords = "Chemoradiation, Cure, EGFR mutation, Locally advanced setting, Lung cancer",
author = "Katsuyuki Hotta and Jiichiro Sasaki and Sho Saeki and Nagio Takigawa and Kuniaki Katsui and Koichi Takayama and Naoyuki Nogami and Yoshiyuki Shioyama and Akihiro Bessho and Junji Kishimoto and Mitsune Tanimoto and Katsuyuki Kiura and Yukito Ichinose",
year = "2015",
month = "8",
day = "8",
doi = "10.1016/j.cllc.2015.08.004",
language = "English",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",

}

TY - JOUR

T1 - Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer

T2 - The LOGIK0902/OLCSG0905 Intergroup Study Protocol

AU - Hotta, Katsuyuki

AU - Sasaki, Jiichiro

AU - Saeki, Sho

AU - Takigawa, Nagio

AU - Katsui, Kuniaki

AU - Takayama, Koichi

AU - Nogami, Naoyuki

AU - Shioyama, Yoshiyuki

AU - Bessho, Akihiro

AU - Kishimoto, Junji

AU - Tanimoto, Mitsune

AU - Kiura, Katsuyuki

AU - Ichinose, Yukito

PY - 2015/8/8

Y1 - 2015/8/8

N2 - Herein, we describe an ongoing phase II trial in patients with locally advanced non-small-cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR). Patients with chemotherapy-naive locally advanced disease with active EGFR mutations will receive the induction treatment, specified as gefitinib monotherapy (250 mg/body) for 8 weeks. Patients whose disease has not progressed during the induction therapy will receive cisplatin and docetaxel (40 mg/m2) on days 1, 8, 29, and 36, and concurrent 3-dimensional conformal thoracic radiotherapy with a single daily fraction of 2 Gy, for 5 consecutive days each week to provide a total dose of 60 Gy. The primary end point is overall survival at 24 months. A target sample size of 21 evaluable patients is considered sufficient to validate an expected rate of 85%, and 60% would be the lower limit of interest, with 80% power and a 1-sided α of 5%. Secondary end points include toxicity, response rate, and overall survival. This study will clarify whether tyrosine kinase inhibitors targeted to EGFR can produce a maximal effect in selected NSCLC patients with the relevant driver mutation, even in the locally advanced setting.

AB - Herein, we describe an ongoing phase II trial in patients with locally advanced non-small-cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR). Patients with chemotherapy-naive locally advanced disease with active EGFR mutations will receive the induction treatment, specified as gefitinib monotherapy (250 mg/body) for 8 weeks. Patients whose disease has not progressed during the induction therapy will receive cisplatin and docetaxel (40 mg/m2) on days 1, 8, 29, and 36, and concurrent 3-dimensional conformal thoracic radiotherapy with a single daily fraction of 2 Gy, for 5 consecutive days each week to provide a total dose of 60 Gy. The primary end point is overall survival at 24 months. A target sample size of 21 evaluable patients is considered sufficient to validate an expected rate of 85%, and 60% would be the lower limit of interest, with 80% power and a 1-sided α of 5%. Secondary end points include toxicity, response rate, and overall survival. This study will clarify whether tyrosine kinase inhibitors targeted to EGFR can produce a maximal effect in selected NSCLC patients with the relevant driver mutation, even in the locally advanced setting.

KW - Chemoradiation

KW - Cure

KW - EGFR mutation

KW - Locally advanced setting

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84941794474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941794474&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2015.08.004

DO - 10.1016/j.cllc.2015.08.004

M3 - Article

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -